- Home
- RPRX vs DECK Comparison
RPRX vs DECK Comparison
Compare RPRX & DECK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- DECK
- Stock Information
- Founded
- RPRX 1996
- DECK 1973
- Country
- RPRX United States
- DECK United States
- Employees
- RPRX N/A
- DECK N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- DECK Shoe Manufacturing
- Sector
- RPRX Health Care
- DECK Consumer Discretionary
- Exchange
- RPRX Nasdaq
- DECK Nasdaq
- Market Cap
- RPRX 16.2B
- DECK 14.1B
- IPO Year
- RPRX 2020
- DECK 1993
- Fundamental
- Price
- RPRX $39.15
- DECK $83.03
- Analyst Decision
- RPRX Strong Buy
- DECK Buy
- Analyst Count
- RPRX 3
- DECK 21
- Target Price
- RPRX $46.00
- DECK $122.16
- AVG Volume (30 Days)
- RPRX 3.8M
- DECK 5.5M
- Earning Date
- RPRX 11-05-2025
- DECK 10-23-2025
- Dividend Yield
- RPRX 2.25%
- DECK N/A
- EPS Growth
- RPRX N/A
- DECK 18.83
- EPS
- RPRX 1.75
- DECK 6.75
- Revenue
- RPRX $2,349,844,000.00
- DECK $5,244,323,000.00
- Revenue This Year
- RPRX $36.16
- DECK $9.84
- Revenue Next Year
- RPRX $2.04
- DECK $7.36
- P/E Ratio
- RPRX $22.36
- DECK $11.96
- Revenue Growth
- RPRX 3.70
- DECK 12.62
- 52 Week Low
- RPRX $24.05
- DECK $78.91
- 52 Week High
- RPRX $41.24
- DECK $223.98
- Technical
- Relative Strength Index (RSI)
- RPRX 58.49
- DECK 41.27
- Support Level
- RPRX $38.82
- DECK $80.23
- Resistance Level
- RPRX $40.01
- DECK $86.69
- Average True Range (ATR)
- RPRX 1.19
- DECK 2.53
- MACD
- RPRX 0.03
- DECK 0.77
- Stochastic Oscillator
- RPRX 60.68
- DECK 54.37
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About DECK Deckers Outdoor Corporation
Founded in 1973, California-based Deckers designs and sells casual and performance footwear, apparel, and accessories. In fiscal 2025, Ugg and Hoka accounted for 51% and 45% of total sales, respectively. The firm also markets niche brands Teva and Ahnu. Deckers produces most of its sales through wholesale partnerships but also operates e-commerce in more than 50 countries and about 180 company-operated stores. It generated 64% of its fiscal 2025 sales in the United States.